BioLife Solutions (NASDAQ:BLFS - Get Free Report) was downgraded by investment analysts at StockNews.com from a "hold" rating to a "sell" rating in a note issued to investors on Monday.
Several other analysts have also recently commented on BLFS. KeyCorp raised their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a research note on Friday, December 13th. HC Wainwright lifted their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Northland Securities boosted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 8th. Finally, Benchmark reaffirmed a "buy" rating and issued a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $29.86.
View Our Latest Analysis on BioLife Solutions
BioLife Solutions Stock Performance
Shares of BioLife Solutions stock traded down $1.92 on Monday, reaching $20.52. 405,758 shares of the stock were exchanged, compared to its average volume of 359,078. The firm has a market capitalization of $964.39 million, a PE ratio of -19.46 and a beta of 2.04. BioLife Solutions has a 1-year low of $14.84 and a 1-year high of $29.55. The business has a fifty day moving average price of $26.00 and a two-hundred day moving average price of $25.51. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03.
BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The business had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. During the same period in the prior year, the business posted ($0.21) EPS. As a group, research analysts anticipate that BioLife Solutions will post -0.3 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, insider Sarah Aebersold sold 5,771 shares of BioLife Solutions stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total transaction of $130,770.86. Following the completion of the sale, the insider now owns 80,094 shares in the company, valued at approximately $1,814,930.04. This trade represents a 6.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Troy Wichterman sold 987 shares of the company's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.02, for a total transaction of $26,668.74. Following the completion of the transaction, the chief financial officer now owns 121,779 shares in the company, valued at approximately $3,290,468.58. This trade represents a 0.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 72,066 shares of company stock valued at $1,688,947. Corporate insiders own 2.20% of the company's stock.
Institutional Trading of BioLife Solutions
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC acquired a new stake in BioLife Solutions in the 4th quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in BioLife Solutions in the fourth quarter valued at approximately $31,000. 1620 Investment Advisors Inc. grew its holdings in BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock valued at $60,000 after purchasing an additional 675 shares during the period. Smartleaf Asset Management LLC increased its position in BioLife Solutions by 27.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider's stock worth $117,000 after purchasing an additional 950 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of BioLife Solutions in the 4th quarter valued at $171,000. 93.24% of the stock is owned by hedge funds and other institutional investors.
About BioLife Solutions
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Further Reading
Before you consider BioLife Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.
While BioLife Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
